Our Pricing

Complete Wegovy Dosing Schedule for UK Patients

Understanding the wegovy dose schedule uk is essential for successful weight loss outcomes. At Cured Pharmacy, our UK-registered clinical team guides patients through the complete five-stage titration process, ensuring safe dose escalation whilst minimising side effects. Wegovy (semaglutide) follows a structured 16-week escalation protocol designed to optimise tolerance and efficacy.

How the Wegovy Dose Schedule Works

Wegovy follows a carefully designed dose escalation schedule over 16 weeks, gradually increasing from 0.25 mg to the maintenance dose of 2.4 mg weekly [1]. This titration approach allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation, significantly reducing the likelihood of gastrointestinal side effects.

The five-dose schedule is: 0.25 mg (weeks 1-4), 0.5 mg (weeks 5-8), 1 mg (weeks 9-12), 1.7 mg (weeks 13-16), and 2.4 mg (week 17 onwards) [1]. Each pen is pre-filled with a single dose strength, eliminating any confusion about dosing. UK prescribers may adjust this schedule based on individual tolerance, though most patients progress through all stages without issue.

Clinical data from the STEP trials showed that patients who completed the full titration schedule experienced average weight loss of 14.9% of initial body weight over 68 weeks, compared to 2.4% with placebo [2]. The gradual escalation is critical to achieving these outcomes whilst maintaining treatment adherence.

Week-by-Week Wegovy Dosing Schedule UK

During weeks 1-4, you'll inject 0.25 mg once weekly. This initial dose is sub-therapeutic, meaning it's designed purely for tolerance building rather than significant weight loss. Most patients report minimal side effects at this stage, with some noticing slight appetite reduction.

Weeks 5-8 increase to 0.5 mg weekly, where many patients begin experiencing noticeable appetite suppression and early weight loss. Mild nausea may occur during the first week at this dose but typically resolves within 3-5 days. Weeks 9-12 progress to 1 mg weekly, often considered the threshold where metabolic effects become pronounced.

The 1.7 mg dose (weeks 13-16) represents the penultimate step, with many patients achieving substantial weight loss momentum by this stage. Finally, the 2.4 mg maintenance dose from week 17 onwards delivers the full therapeutic effect demonstrated in clinical trials [1][2].

What to Expect at Each Dose Level

At 0.25 mg and 0.5 mg, expect gradual appetite changes and possible mild bloating. The 1 mg dose often marks a turning point where food noise significantly diminishes and portion sizes naturally decrease. At 1.7 mg and 2.4 mg, most patients report feeling satisfied with smaller meals and reduced cravings between eating occasions. Your UK prescriber may recommend staying at a lower dose if you're achieving your weight loss goals with minimal side effects, though 2.4 mg remains the licensed maintenance dose for optimal outcomes [1].

Managing Side Effects During Dose Escalation

Gastrointestinal side effects—particularly nausea, constipation, and occasional vomiting—are most common during the first 2-3 days after each dose increase [3]. These effects typically subside as your body adapts to the new dose level. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce discomfort.

If side effects persist beyond one week at a new dose, contact your UK prescriber before your next injection. They may recommend delaying the escalation by 2-4 weeks, which is a common and safe adjustment. Staying well-hydrated (2-3 litres daily) helps manage constipation, whilst ginger tea or prescription anti-emetics can address persistent nausea.

Severe or persistent vomiting, signs of pancreatitis (severe upper abdominal pain), or symptoms of gallbladder problems require immediate medical attention. These are rare but serious side effects that warrant discontinuation and clinical review [3].

Wegovy Dose Schedule vs Other Weight Loss Injections

Wegovy's 16-week titration schedule is longer than Saxenda (liraglutide), which escalates over just 5 weeks to a daily 3 mg dose. The extended Wegovy schedule reflects semaglutide's longer half-life and more potent GLP-1 receptor activation, requiring slower adaptation [4].

Mounjaro (tirzepatide) follows a similar gradual approach with five dose levels over 20 weeks, though it uses a dual GIP/GLP-1 mechanism. Both Wegovy and Mounjaro offer once-weekly convenience compared to Saxenda's daily injections, improving long-term adherence in clinical practice.

The structured dose schedule is a regulatory requirement, not optional. UK prescribers cannot skip dose levels or accelerate the schedule beyond MHRA-approved guidelines, ensuring patient safety remains paramount throughout treatment.

Choosing Between Wegovy and Alternative Treatments

Your UK prescriber will consider your BMI, weight loss goals, previous treatment response, and tolerance for injection frequency when recommending between Wegovy, Saxenda, or Mounjaro. All three require prescription-only access following clinical assessment. At Cured Pharmacy, transparent pricing from £79.00 for Wegovy allows you to compare costs before your consultation, with no hidden fees or surprise charges at checkout.

What Happens If You Miss a Dose

If you miss a Wegovy injection and it's been less than 5 days since your scheduled dose, inject as soon as you remember and continue your regular weekly schedule. If more than 5 days have passed, skip the missed dose entirely and resume with your next scheduled injection [1].

Missing multiple consecutive doses may require restarting at a lower dose level to re-establish tolerance. If you've missed two or more weeks, contact your UK prescriber before injecting—they'll advise whether to continue at your current dose or step back to the previous level.

Setting a consistent weekly injection day (many patients choose Friday or Saturday evenings) and phone reminders significantly improves adherence. Wegovy pens can be stored in the refrigerator for up to 28 days after first use, allowing flexibility if you need to adjust your injection day by 1-2 days occasionally.

Long-Term Use and Maintenance Dosing

Once you reach the 2.4 mg maintenance dose at week 17, you'll continue this dose for as long as treatment remains clinically appropriate and effective. Clinical trials followed patients for up to 68 weeks, demonstrating sustained weight loss and metabolic improvements throughout this period [2].

Weight loss typically plateaus between months 9-12, after which the focus shifts to weight maintenance and preventing regain. Your UK prescriber will schedule regular reviews (typically every 3-6 months) to assess ongoing suitability, monitor for side effects, and evaluate whether continued treatment aligns with your health goals.

Discontinuing Wegovy often results in gradual weight regain, as demonstrated in extension studies where patients who stopped treatment regained approximately two-thirds of lost weight over 52 weeks [5]. This underscores that Wegovy is a long-term management tool rather than a short-term intervention, requiring ongoing lifestyle modifications alongside pharmacotherapy for sustained results.

When to Consider Dose Adjustment or Discontinuation

Some patients achieve their target weight loss at doses lower than 2.4 mg and may remain at 1 mg or 1.7 mg long-term with prescriber approval. Conversely, if you experience minimal weight loss (less than 5% of initial body weight) after reaching 2.4 mg for 12 weeks, your prescriber may recommend discontinuing treatment and exploring alternative options. All dosing decisions require clinical oversight and should never be self-adjusted.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy): Reports of gastrointestinal adverse reactions. Drug Safety Update, 16(8). https://www.gov.uk/drug-safety-update
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
5. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity.